UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 1405-3
Program Prior Authorization/Notification
Medication Sunlenca® (lenacapavir)
P&T Approval Date 3/2023, 3/2024, 3/2025
Effective Date 6/1/2025
1. Background:
Sunlenca (lenacapavir), a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, in
combination with other antiretroviral(s), is indicated for the treatment of HIV-1 infection in
heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their
current antiretroviral regimen due to resistance, intolerance, or safety considerations.
Members will be required to meet the coverage criteria below.
2. Coverage Criteriaa:
A. Authorization
1. Sunlenca will be approved based on both of the following criteria:
a. Patient has been diagnosed with multidrug-resistant HIV-1 infection
-AND-
b. Patient is currently taking or will be prescribed an optimized background antiretroviral
regimen
Authorization will be issued for 1 month.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Sunlenca [Package Insert]. Foster City, CA: Gilead Sciences, Inc.; November 2024.
© 2025 UnitedHealthcare Services, Inc.
1
Program Prior Authorization/Notification - Sunlenca® (lenacapavir)
Change Control
3/2023 New program.
3/2024 Annual review with no changes to clinical criteria. Updated reference.
3/2025 Annual review with no changes to clinical criteria. Updated reference.
© 2025 UnitedHealthcare Services, Inc.
2